ReviewWorld journal of experimental medicine2026
Myocardiocyte senescence in ischemic heart disease and breathome changes.
Review in World journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging is an irreversible and continuous process characterized by metabolic alterations induced by epigenomic changes. Myocardiocytes, a type of cardiac cell, are among the cells affected by this process. These changes affect cardiometabolic homeostasis at both cellular and subcellular levels. Consequently, dysregulation occurs between the protective and aggressive systems of myocardiocytes, leading to an increased prevalence of the aggressive system. This imbalance weakens the protective system against harmful factors, such as ischemia. As a result, ischemic heart disease develops, and pathological cardiometabolic changes in myocardiocytes progress with each ischemia-reperfusion event. These cardiometabolic alterations serve as biomarkers (outcomes) of ischemic myocardiocytes released into the bloodstream. The detection of these biomarkers in exhaled breath, in the form of volatile organic compounds (VOCs), is feasible using various types of mass spectrometers, including the proton transfer reaction time of flight mass spectrometer. Exhaled VOCs can be utilized as biomarkers of the biological age of myocardiocytes by measuring the concentration of specific VOCs associated with cardiometabolic changes and ischemic myocardiocytes. This article explores the relationship between myocardiocyte aging and the development of ischemic heart disease, as well as the changes in exhaled VOCs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.